Logo image of XAIR

BEYOND AIR INC (XAIR) Stock Overview

NASDAQ:XAIR - US08862L1035 - Common Stock

2.2 USD
-0.02 (-0.9%)
Last: 9/2/2025, 12:55:37 PM

XAIR Key Statistics, Chart & Performance

Key Statistics
52 Week High13.52
52 Week Low2.02
Market Cap11.51M
Shares5.23M
Float4.61M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-6.61
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO05-07 2019-05-07
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


XAIR short term performance overview.The bars show the price performance of XAIR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

XAIR long term performance overview.The bars show the price performance of XAIR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of XAIR is 2.2 USD. In the past month the price decreased by -22.38%. In the past year, price decreased by -74.89%.

BEYOND AIR INC / XAIR Daily stock chart

XAIR Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.79 228.46B
ISRG INTUITIVE SURGICAL INC 57.8 166.80B
BSX BOSTON SCIENTIFIC CORP 37.51 157.29B
SYK STRYKER CORP 30.24 148.57B
MDT MEDTRONIC PLC 16.93 120.10B
BDX BECTON DICKINSON AND CO 13.24 54.14B
IDXX IDEXX LABORATORIES INC 53.08 51.00B
EW EDWARDS LIFESCIENCES CORP 31.74 47.88B
RMD RESMED INC 28.36 39.65B
GEHC GE HEALTHCARE TECHNOLOGY 15.33 32.61B
DXCM DEXCOM INC 43.66 29.11B
PHG KONINKLIJKE PHILIPS NVR- NY 15.98 26.00B

About XAIR

Company Profile

XAIR logo image Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.

Company Info

BEYOND AIR INC

900 Stewart Ave, Suite 301

Garden City NEW YORK 11530 US

CEO: Steven Lisi

Employees: 107

XAIR Company Website

XAIR Investor Relations

Phone: 15166658200

BEYOND AIR INC / XAIR FAQ

What is the stock price of BEYOND AIR INC today?

The current stock price of XAIR is 2.2 USD. The price decreased by -0.9% in the last trading session.


What is the ticker symbol for BEYOND AIR INC stock?

The exchange symbol of BEYOND AIR INC is XAIR and it is listed on the Nasdaq exchange.


On which exchange is XAIR stock listed?

XAIR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BEYOND AIR INC stock?

12 analysts have analysed XAIR and the average price target is 11.42 USD. This implies a price increase of 419.27% is expected in the next year compared to the current price of 2.2. Check the BEYOND AIR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BEYOND AIR INC worth?

BEYOND AIR INC (XAIR) has a market capitalization of 11.51M USD. This makes XAIR a Nano Cap stock.


How many employees does BEYOND AIR INC have?

BEYOND AIR INC (XAIR) currently has 107 employees.


What are the support and resistance levels for BEYOND AIR INC (XAIR) stock?

BEYOND AIR INC (XAIR) has a resistance level at 2.29. Check the full technical report for a detailed analysis of XAIR support and resistance levels.


Is BEYOND AIR INC (XAIR) expected to grow?

The Revenue of BEYOND AIR INC (XAIR) is expected to grow by 238.81% in the next year. Check the estimates tab for more information on the XAIR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BEYOND AIR INC (XAIR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BEYOND AIR INC (XAIR) stock pay dividends?

XAIR does not pay a dividend.


When does BEYOND AIR INC (XAIR) report earnings?

BEYOND AIR INC (XAIR) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of BEYOND AIR INC (XAIR)?

BEYOND AIR INC (XAIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.61).


What is the Short Interest ratio of BEYOND AIR INC (XAIR) stock?

The outstanding short interest for BEYOND AIR INC (XAIR) is 9.78% of its float. Check the ownership tab for more information on the XAIR short interest.


XAIR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

XAIR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XAIR. XAIR has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XAIR Financial Highlights

Over the last trailing twelve months XAIR reported a non-GAAP Earnings per Share(EPS) of -6.61. The EPS decreased by -303.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -149.8%
ROE -424.25%
Debt/Equity 0.97
Chartmill High Growth Momentum
EPS Q2Q%-466.67%
Sales Q2Q%157.69%
EPS 1Y (TTM)-303.05%
Revenue 1Y (TTM)168.05%

XAIR Forecast & Estimates

12 analysts have analysed XAIR and the average price target is 11.42 USD. This implies a price increase of 419.27% is expected in the next year compared to the current price of 2.2.

For the next year, analysts expect an EPS growth of 18.45% and a revenue growth 238.81% for XAIR


Analysts
Analysts80
Price Target11.42 (419.09%)
EPS Next Y18.45%
Revenue Next Year238.81%

XAIR Ownership

Ownership
Inst Owners20.86%
Ins Owners13.38%
Short Float %9.78%
Short Ratio0.35